Top

Published in:

Open Access 01-12-2015 | Research

Friedreich ataxia in Norway – an epidemiological, molecular and clinical study

Authors: Iselin Marie Wedding, Mette Kroken, Sandra Pilar Henriksen, Kaja Kristine Selmer, Torunn Fiskerstrand, Per Morten Knappskog, Tone Berge, Chantal ME Tallaksen

Published in: Orphanet Journal of Rare Diseases | Issue 1/2015

Abstract

Background

Friedreich ataxia is an autosomal recessive hereditary spinocerebellar disorder, characterized by progressive limb and gait ataxia due to proprioceptive loss, often complicated by cardiomyopathy, diabetes and skeletal deformities. Friedreich ataxia is the most common hereditary ataxia, with a reported prevalence of 1:20 000 – 1:50 000 in Central Europe. Previous reports from south Norway have found a prevalence varying from 1:100 000 – 1:1 350 000; no studies are previously done in the rest of the country.

Methods

In this cross-sectional study, Friedreich ataxia patients were identified through colleagues in neurological, pediatric and genetic departments, hospital archives searches, patients’ associations, and National Centre for Rare Disorders. All included patients, carriers and controls were investigated clinically and molecularly with genotype characterization including size determination of GAA repeat expansions and frataxin measurements. 1376 healthy blood donors were tested for GAA repeat expansion for carrier frequency analysis.

Results

Twenty-nine Friedreich ataxia patients were identified in Norway, of which 23 were ethnic Norwegian, corresponding to a prevalence of 1:176 000 and 1:191 000, respectively. The highest prevalence was seen in the north. Carrier frequency of 1:196 (95 % CI = [1:752–1:112]) was found. Homozygous GAA repeat expansions in the FXN gene were found in 27/29, while two patients were compound heterozygous with c.467 T < C, L157P and the deletion (g.120032_122808del) including exon 5a. Two additional patients were heterozygous for GAA repeat expansions only. Significant differences in the level of frataxin were found between the included patients (N = 27), carriers (N = 37) and controls (N = 27).

Conclusions

In this first thorough study of a complete national cohort of Friedreich ataxia patients, and first nation-wide study of Friedreich ataxia in Norway, the prevalence of Friedreich ataxia in Norway is lower than in Central Europe, but higher than in the last Norwegian report, and as expected from migration studies. A south–north prevalence gradient is present. Based on Hardy Weinberg’s equilibrium, the carrier frequency of 1:196 is consistent with the observed prevalence. All genotypes, and typical and atypical phenotypes were present in the Norwegian population. The patients were phenotypically similar to European cohorts. Frataxin was useful in the diagnostic work-up of heterozygous symptomatic cases.

Available only for authorised users

Bidichandani SI, Delatycki MB. Friedreich Ataxia. Pagon R, Adam M, HH A, editors. Seattle, USA: University of Washington, Seattle; 1998 (Updated 2014 Jul 24).

Pandolfo M. Friedreich ataxia: the clinical picture. J Neurol. 2009;256 Suppl 1:3–8. doi:10.1007/s00415-009-1002-3.CrossRefPubMed

Durr A, Cossee M, Agid Y, Campuzano V, Mignard C, Penet C, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med. 1996;335(16):1169–75. doi:10.1056/nejm199610173351601.CrossRefPubMed

Parkinson MH, Boesch S, Nachbauer W, Mariotti C, Giunti P. Clinical features of Friedreich’s ataxia: classical and atypical phenotypes. J Neurochem. 2013;126 Suppl 1:103–17. doi:10.1111/jnc.12317.CrossRefPubMed

Koeppen AH, Mazurkiewicz JE. Friedreich ataxia: neuropathology revised. J Neuropathol Exp Neurol. 2013;72(2):78–90. doi:10.1097/NEN.0b013e31827e5762.CrossRefPubMed

Harding AE. Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain. 1981;104(3):589–620.CrossRefPubMed

Labuda M, Labuda D, Miranda C, Poirier J, Soong BW, Barucha NE, et al. Unique origin and specific ethnic distribution of the Friedreich ataxia GAA expansion. Neurology. 2000;54(12):2322–4.CrossRefPubMed

Skre H. Friedreich’s ataxia in Western Norway. Clin Genet. 1975;7(4):287–98.CrossRefPubMed

Koht J, Tallaksen CM. Cerebellar ataxia in the eastern and southern parts of Norway. Acta Neurol Scand Suppl. 2007;187:76–9. doi:10.1111/j.1600-0404.2007.00853.x.CrossRefPubMed

10.

Erichsen AK, Koht J, Stray-Pedersen A, Abdelnoor M, Tallaksen CM. Prevalence of hereditary ataxia and spastic paraplegia in southeast Norway: a population-based study. Brain. 2009;132(Pt 6):1577–88. doi:10.1093/brain/awp056.CrossRefPubMed

11.

Campuzano V, Montermini L, Molto MD, Pianese L, Cossee M, Cavalcanti F, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996;271(5254):1423–7.CrossRefPubMed

12.

Tzoulis C, Engelsen BA, Telstad W, Aasly J, Zeviani M, Winterthun S, et al. The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases. Brain. 2006;129(Pt 7):1685–92. doi:10.1093/brain/awl097.CrossRefPubMed

13.

Vankan P. Prevalence gradients of Friedreich’s ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge. J Neurochem. 2013;126 Suppl 1:11–20. doi:10.1111/jnc.12215.CrossRefPubMed

14.

Lamont PJ, Davis MB, Wood NW. Identification and sizing of the GAA trinucleotide repeat expansion of Friedreich’s ataxia in 56 patients. Clinical and genetic correlates. Brain. 1997;120(Pt 4):673–80.CrossRefPubMed

15.

Cossee M, Durr A, Schmitt M, Dahl N, Trouillas P, Allinson P, et al. Friedreich’s ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol. 1999;45(2):200–6.CrossRefPubMed

16.

Zuhlke CH, Dalski A, Habeck M, Straube K, Hedrich K, Hoeltzenbein M, et al. Extension of the mutation spectrum in Friedreich’s ataxia: detection of an exon deletion and novel missense mutations. Eur J Hum Genet. 2004;12(11):979–82. doi:10.1038/sj.ejhg.5201257.CrossRefPubMed

17.

Anheim M, Mariani LL, Calvas P, Cheuret E, Zagnoli F, Odent S, et al. Exonic deletions of FXN and early-onset Friedreich ataxia. Arch Neurol. 2012;69(7):912–6. doi:10.1001/archneurol.2011.834.CrossRefPubMed

18.

Pastore A, Puccio H. Frataxin: a protein in search for a function. J Neurochem. 2013;126 Suppl 1:43–52. doi:10.1111/jnc.12220.CrossRefPubMed

19.

Matilla-Duenas A, Ashizawa T, Brice A, Magri S, McFarland KN, Pandolfo M, et al. Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias. Cerebellum (London, England). 2014;13(2):269–302. doi:10.1007/s12311-013-0539-y.PubMedCentralCrossRef

20.

Nachbauer W, Wanschitz J, Steinkellner H, Eigentler A, Sturm B, Hufler K, et al. Correlation of frataxin content in blood and skeletal muscle endorses frataxin as a biomarker in Friedreich ataxia. Mov Disord. 2011;26(10):1935–8. doi:10.1002/mds.23789.CrossRefPubMed

21.

Deutsch EC, Santani AB, Perlman SL, Farmer JM, Stolle CA, Marusich MF, et al. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol Genet Metab. 2010;101(2–3):238–45. doi:10.1016/j.ymgme.2010.07.001.PubMedCentralCrossRefPubMed

22.

Deutsch EC, Oglesbee D, Greeley NR, Lynch DR. Usefulness of frataxin immunoassays for the diagnosis of Friedreich ataxia. J Neurol Neurosurg Psychiatry. 2014;85(9):994–1002. doi:10.1136/jnnp-2013-306788.CrossRefPubMed

23.

Pandolfo M. Molecular basis of Friedreich ataxia. Mov Disord. 2001;16(5):815–21.CrossRefPubMed

24.

Pandolfo M. Friedreich ataxia. Handb Clin Neurol. 2012;103:275–94. doi:10.1016/b978-0-444-51892-7.00017-6.CrossRefPubMed

25.

Montermini L, Richter A, Morgan K, Justice CM, Julien D, Castellotti B, et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol. 1997;41(5):675–82. doi:10.1002/ana.410410518.CrossRefPubMed

26.

Cossee M, Schmitt M, Campuzano V, Reutenauer L, Moutou C, Mandel JL, et al. Evolution of the Friedreich’s ataxia trinucleotide repeat expansion: founder effect and premutations. Proc Natl Acad Sci U S A. 1997;94(14):7452–7.PubMedCentralCrossRefPubMed

27.

Montermini L, Andermann E, Labuda M, Richter A, Pandolfo M, Cavalcanti F, et al. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum Mol Genet. 1997;6(8):1261–6.CrossRefPubMed

28.

Statistics Norway. www.ssb.no. Accessed 30 November 2014.

29.

Tallaksen CME, Dürr A. SPATAX- European Network for Hereditary Spinocerebellar Degenerative Disorders. Acta Neurol Scand. 2003;107(6):432–3. doi:10.1034/j.1600-0404.2003.00125_18.x.CrossRef

30.

SPATAX Network. https://spatax.wordpress.com. Accessed 01 January 2013.

31.

Schmitz-Hubsch T, du Montcel S, Baliko L, Berciano J, Boesch S, Depondt C. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66:1717–20.CrossRefPubMed

32.

Ciotti P, Di Maria E, Bellone E, Ajmar F, Mandich P. Triplet repeat primed PCR (TP PCR) in molecular diagnostic testing for Friedreich ataxia. J Mol Diagn. 2004;6(4):285–9. doi:10.1016/s1525-1578(10)60523-5.PubMedCentralCrossRefPubMed

33.

Pandolfo M. Friedreich ataxia: Detection of GAA repeat expansions and frataxin point mutations. Methods Mol Med. 2006;126:197–216. doi:10.1385/1-59745-088-x:197.PubMed

34.

Schols L, Amoiridis G, Przuntek H, Frank G, Epplen JT, Epplen C. Friedreich’s ataxia. Revision of the phenotype according to molecular genetics. Brain. 1997;120(Pt 12):2131–40.CrossRefPubMed

35.

Willis JH, Isaya G, Gakh O, Capaldi RA, Marusich MF. Lateral-flow immunoassay for the frataxin protein in Friedreich’s ataxia patients and carriers. Mol Genet Metab. 2008;94(4):491–7. doi:10.1016/j.ymgme.2008.03.019.PubMedCentralCrossRefPubMed

36.

Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M, et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain. 2010;133(Pt 3):771–86. doi:10.1093/brain/awq007.PubMedCentralCrossRefPubMed

37.

Filla A, DeMichele G, Caruso G, Marconi R, Campanella G. Genetic data and natural history of Friedreich’s disease: a study of 80 Italian patients. J Neurol. 1990;237(6):345–51.CrossRefPubMed

38.

Delatycki MB, Paris DB, Gardner RJ, Nicholson GA, Nassif N, Storey E, et al. Clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet. 1999;87(2):168–74.CrossRefPubMed

39.

McCabe DJ, Ryan F, Moore DP, McQuaid S, King MD, Kelly A, et al. Typical Friedreich’s ataxia without GAA expansions and GAA expansion without typical Friedreich’s ataxia. J Neurol. 2000;247(5):346–55.CrossRefPubMed

40.

Salehi MH, Houshmand M, Aryani O, Kamalidehghan B, Khalili E. Molecular and clinical investigation of Iranian patients with Friedreich ataxia. Iran Biomed J. 2014;18(1):28–33.PubMedCentralPubMed

41.

Reetz K, Dogan I, Costa AS, Dafotakis M, Fedosov K, Giunti P, et al. Biological and clinical characteristics of the European Friedreich’s Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurol. 2015;14(2):174–82. doi:10.1016/s1474-4422(14)70321-7.CrossRefPubMed

42.

Jonasson J, Juvonen V, Sistonen P, Ignatius J, Johansson D, Bjorck EJ, et al. Evidence for a common Spinocerebellar ataxia type 7 (SCA7) founder mutation in Scandinavia. Eur J Hum Genet. 2000;8(12):918–22. doi:10.1038/sj.ejhg.5200557.CrossRefPubMed

43.

Juvonen V, Kulmala SM, Ignatius J, Penttinen M, Savontaus ML. Dissecting the epidemiology of a trinucleotide repeat disease - example of FRDA in Finland. Hum Genet. 2002;110(1):36–40. doi:10.1007/s00439-001-0642-x.CrossRefPubMed

44.

Dupuy BM, Stenersen M, Lu TT, Olaisen B. Geographical heterogeneity of Y-chromosomal lineages in Norway. Forensic Sci Int. 2006;164(1):10–9. doi:10.1016/j.forsciint.2005.11.009.CrossRefPubMed

45.

Gedde-Dahl Jr T. Population structure in Norway. Inbreeding, distance and kinship. Hereditas. 1973;73(2):211–32.CrossRefPubMed

46.

Saugstad LF. Inbreeding in Norway. Ann Hum Genet. 1977;40(4):481–91.CrossRefPubMed

47.

Surén P, Grjibovski A, Stoltenberg C. Inngifte i Norge. Omfang og medisinske konsekvenser. Oslo: Norwegian Institute of Public Health; 2007.

48.

Saugstad LF. The relationship between inbreeding, migration and population density in Norway. Ann Hum Genet. 1977;40(3):331–41.CrossRefPubMed

49.

Burk K, Malzig U, Wolf S, Heck S, Dimitriadis K, Schmitz-Hubsch T, et al. Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Mov Disord. 2009;24(12):1779–84. doi:10.1002/mds.22660.CrossRefPubMed

50.

Silva CB, Yasuda CL, D'Abreu A, Cendes F, Lopes-Cendes I, Franca Jr MC. Neuroanatomical correlates of depression in Friedreich’s ataxia: a voxel-based morphometry study. Cerebellum. 2013;12(3):429–36. doi:10.1007/s12311-012-0424-0.CrossRefPubMed

51.

Lagedrost SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlman SL, et al. Idebenone in Friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA). Am Heart J. 2011;161(3):639–45.e1. doi:10.1016/j.ahj.2010.10.038.CrossRefPubMed

52.

Meier T, Perlman SL, Rummey C, Coppard NJ, Lynch DR. Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich’s ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study. J Neurol. 2012;259(2):284–91. doi:10.1007/s00415-011-6174-y.CrossRefPubMed

53.

Tsou AY, Paulsen EK, Lagedrost SJ, Perlman SL, Mathews KD, Wilmot GR, et al. Mortality in Friedreich ataxia. J Neurol Sci. 2011;307(1–2):46–9. doi:10.1016/j.jns.2011.05.023.CrossRefPubMed

54.

Wilson CL, Fahey MC, Corben LA, Collins VR, Churchyard AJ, Lamont PJ, et al. Quality of life in Friedreich ataxia: what clinical, social and demographic factors are important? Eur J Neurol. 2007;14(9):1040–7. doi:10.1111/j.1468-1331.2007.01881.x.CrossRefPubMed

55.

Coppola G, De Michele G, Cavalcanti F, Pianese L, Perretti A, Santoro L, et al. Why do some Friedreich’s ataxia patients retain tendon reflexes? A clinical, neurophysiological and molecular study. J Neurol. 1999;246(5):353–7.CrossRefPubMed

56.

Filla A, De Michele G, Cavalcanti F, Pianese L, Monticelli A, Campanella G, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996;59(3):554–60.PubMedCentralPubMed

57.

Ohshima K, Sakamoto N, Labuda M, Poirier J, Moseley ML, Montermini L, et al. A nonpathogenic GAAGGA repeat in the Friedreich gene: implications for pathogenesis. Neurology. 1999;53(8):1854–7.CrossRefPubMed

58.

Sacca F, Puorro G, Antenora A, Marsili A, Denaro A, Piro R, et al. A combined nucleic acid and protein analysis in Friedreich ataxia: implications for diagnosis, pathogenesis and clinical trial design. PLoS One. 2011;6(3), e17627. doi:10.1371/journal.pone.0017627.PubMedCentralCrossRefPubMed

59.

Xia H, Cao Y, Dai X, Marelja Z, Zhou D, Mo R, et al. Novel frataxin isoforms may contribute to the pathological mechanism of Friedreich ataxia. PLoS One. 2012;7(10), e47847. doi:10.1371/journal.pone.0047847.PubMedCentralCrossRefPubMed

60.

De Michele G, Filla A. Movement disorders: Friedreich ataxia today-preparing for the final battle. Nat Rev Neurol. 2015;11(4):188–90. doi:10.1038/nrneurol.2015.33.CrossRefPubMed

61.

Boehm T, Scheiber-Mojdehkar B, Kluge B, Goldenberg H, Laccone F, Sturm B. Variations of frataxin protein levels in normal individuals. Neurol Sci. 2011;32(2):327–30. doi:10.1007/s10072-010-0326-1.CrossRefPubMed

62.

Sacca F, Marsili A, Puorro G, Antenora A, Pane C, Tessa A, et al. Clinical use of frataxin measurement in a patient with a novel deletion in the FXN gene. J Neurol. 2013;260(4):1116–21. doi:10.1007/s00415-012-6770-5.CrossRefPubMed

63.

Werdelin L, Keiding N. Hereditary ataxias: epidemiological aspects. Neuroepidemiology. 1990;9(6):321–31.CrossRefPubMed

64.

Gudmundsson KR. Prevalence and occurrence of some rare neurological diseases in Iceland. Acta Neurol Scand. 1969;45(1):114–8.CrossRefPubMed

65.

Marino TC, Zaldivar YG, Mesa JM, Mederos LA, Rodriguez RA, Gotay DA, et al. Low predisposition to instability of the Friedreich ataxia gene in Cuban population. Clin Genet. 2010;77(6):598–600. doi:10.1111/j.1399-0004.2009.01361.x.CrossRefPubMed

66.

Singh I, Faruq M, Mukherjee O, Jain S, Pal PK, Srivastav MV, et al. North and South Indian populations share a common ancestral origin of Friedreich’s ataxia but vary in age of GAA repeat expansion. Ann Hum Genet. 2010;74(3):202–10. doi:10.1111/j.1469-1809.2010.00569.x.CrossRefPubMed

67.

Monticelli A, Giacchetti M, De Biase I, Pianese L, Turano M, Pandolfo M, et al. New clues on the origin of the Friedreich ataxia expanded alleles from the analysis of new polymorphisms closely linked to the mutation. Hum Genet. 2004;114(5):458–63. doi:10.1007/s00439-004-1089-7.CrossRefPubMed

Title: Friedreich ataxia in Norway – an epidemiological, molecular and clinical study
Authors: Iselin Marie Wedding
Mette Kroken
Sandra Pilar Henriksen
Kaja Kristine Selmer
Torunn Fiskerstrand
Per Morten Knappskog
Tone Berge
Chantal ME Tallaksen
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Orphanet Journal of Rare Diseases / Issue 1/2015
Electronic ISSN: 1750-1172
DOI: https://doi.org/10.1186/s13023-015-0328-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Friedreich ataxia in Norway – an epidemiological, molecular and clinical study

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Self-administered version of the Fabry-associated pain questionnaire for adult patients

Genotype-phenotype associations in French patients with phenylketonuria and importance of genotype for full assessment of tetrahydrobiopterin responsiveness

Molecular and clinical analysis of TRPC6 and AGTR1 genes in patients with pulmonary arterial hypertension

A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy

Cost effective assay choice for rare disease study designs

A meta-analysis of randomized double-blind clinical trials in CMT1A to assess the change from baseline in CMTNS and ONLS scales after one year of treatment